{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:38:11Z","timestamp":1784191091524,"version":"3.55.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1097\/inf.0000000000000965","type":"journal-article","created":{"date-parts":[[2015,10,17]],"date-time":"2015-10-17T14:01:32Z","timestamp":1445090492000},"page":"e48-e59","source":"Crossref","is-referenced-by-count":12,"title":["Immunogenicity and Safety of a 3- and 4-dose Vaccination Series of a Meningococcal ACWY Conjugate Vaccine in Infants"],"prefix":"10.1097","volume":"35","author":[{"given":"Stan L.","family":"Block","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Shepard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartley","family":"Garfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Dull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Smolenov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl 2","key":"R1-20-20210202","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2011.12.062","article-title":"Meningococcal disease: clinical presentation and sequelae.","volume":"30","author":"Pace","year":"2012","journal-title":"Vaccine"},{"key":"R2-20-20210202","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/INF.0b013e3181d3ce32","article-title":"Groupe des pediatres et microbiologistes de lObservatoire National des Meningites. Association of meningococcal phenotypes and genotypes with clinical characteristics and mortality of meningitis in children.","volume":"29","author":"Levy","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R3-20-20210202","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/649209","article-title":"Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease.","volume":"50","author":"Cohn","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R4-20-20210202","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1016\/j.vaccine.2012.03.011","article-title":"Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines.","volume":"30","author":"Ladhani","year":"2012","journal-title":"Vaccine"},{"issue":"suppl 2","key":"R5-20-20210202","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease.","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"R6-20-20210202","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease.","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metr"},{"key":"R7-20-20210202","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1586\/14760584.5.4.445","article-title":"Experience with MCV-4, a meningococcal, diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135.","volume":"5","author":"Keyserling","year":"2006","journal-title":"Expert Rev Vaccines"},{"key":"R8-20-20210202","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2147\/IDR.S12716","article-title":"Critical appraisal of a quadrivalent CRM(197) conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo) in the context of treatment and prevention of invasive disease.","volume":"4","author":"Broker","year":"2011","journal-title":"Infect Drug Resist"},{"key":"R9-20-20210202","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.2165\/11209580-000000000-00000","article-title":"Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix).","volume":"72","author":"Croxtall","year":"2012","journal-title":"Drugs"},{"key":"R10-20-20210202","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jama.2007.29-c","article-title":"Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.","volume":"299","author":"Snape","year":"2008","journal-title":"JAMA"},{"key":"R11-20-20210202","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/INF.0b013e31823dce5c","article-title":"Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants.","volume":"31","author":"Klein","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R12-20-20210202","doi-asserted-by":"crossref","first-page":"7865","DOI":"10.1016\/j.vaccine.2010.09.092","article-title":"Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age.","volume":"28","author":"Halperin","year":"2010","journal-title":"Vaccine"},{"key":"R13-20-20210202","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1086\/599117","article-title":"V59P13 Study Group. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.","volume":"49","author":"Jackson","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R14-20-20210202","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1128\/CVI.00207-09","article-title":"Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra.","volume":"16","author":"Reisinger","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"R15-20-20210202","doi-asserted-by":"crossref","first-page":"e868","DOI":"10.1016\/j.ijid.2010.03.017","article-title":"Safety and immunogenicity of an investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America.","volume":"14","author":"Stamboulian","year":"2010","journal-title":"Int J Infect Dis"},{"key":"R16-20-20210202","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijid.2014.03.1390","article-title":"Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers.","volume":"26","author":"Tregnaghi","year":"2014","journal-title":"Int J Infect Dis"},{"key":"R17-20-20210202","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4161\/hv.27051","article-title":"Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age.","volume":"10","author":"Nolan","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"R19-20-20210202","first-page":"527","article-title":"Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, CDC. Use of MenACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2013.","volume":"63","author":"MacNeil","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R20-20-20210202","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1016\/j.vaccine.2010.04.072","article-title":"Overview of the development and current use of CRM(197) conjugate vaccines for pediatric use.","volume":"28","author":"Shinefield","year":"2010","journal-title":"Vaccine"},{"key":"R21-20-20210202","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.vaccine.2009.01.005","article-title":"The influence of carrier protein on the immunogenicity of simultaneously administered conjugate vaccines in infants.","volume":"27","author":"Pollabauer","year":"2009","journal-title":"Vaccine"},{"issue":"suppl 2","key":"R22-20-20210202","doi-asserted-by":"crossref","first-page":"B112","DOI":"10.1016\/j.vaccine.2009.04.065","article-title":"Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease.","volume":"27","author":"Frasch","year":"2009","journal-title":"Vaccine"},{"key":"R23-20-20210202","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/10543400600719251","article-title":"Statistical considerations for noninferiorityequivalence trials in vaccine development.","volume":"16","author":"Wang","year":"2006","journal-title":"J Biopharm Stat"},{"key":"R24-20-20210202","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies.","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"R25-20-20210202","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/j.vaccine.2013.03.036","article-title":"The B-cell response to a primary and booster course of MenACWY-CRM197 vaccine administered at 2, 4 and 12 months of age.","volume":"31","author":"Blanchard-Rohner","year":"2013","journal-title":"Vaccine"},{"key":"R28-20-20210202","doi-asserted-by":"crossref","first-page":"e72794","DOI":"10.1371\/journal.pone.0072794","article-title":"Immunogenicity of seven-valent pneumococcal conjugate vaccine administered at 6, 14 and 40 weeks of age in South African infants.","volume":"8","author":"Jones","year":"2013","journal-title":"PLoS One"},{"key":"R31-20-20210202","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1542\/peds.2009-3027","article-title":"004 Study Group. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers.","volume":"126","author":"Yeh","year":"2010","journal-title":"Pediatrics"},{"key":"R32-20-20210202","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/INF.0000000000000511","article-title":"Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine manufactured with and without polysorbate 80 given to healthy infants at 2, 3, 4 and 12 months of age.","volume":"34","author":"Gadzinowski","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"R33-20-20210202","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.vaccine.2013.12.034","article-title":"Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants.","volume":"32","author":"Abdelnour","year":"2014","journal-title":"Vaccine"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000000965","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:09:08Z","timestamp":1620954548000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201602000-00020"}},"subtitle":["Results of a Phase 3b, Randomized, Open-label Trial"],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000000965","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}